Conferences EASL 2015
Other Infections
EASL 2015: Hepatitis C Treatment Could Cut HCV Transmission Among UK Gay Men in Half
- Details
- Category: HCV Sexual Transmission
- Published on Wednesday, 17 June 2015 00:00
- Written by Keith Alcorn, Aidsmap
Access to more effective hepatitis C treatment could reduce new infections among men who have sex with men in the United Kingdom by half over the next decade, according to a mathematical modeling study presented at the European Association for the Study of the Liver (EASL) International Liver Congress in Vienna in April.
EASL 2015: Reinfection after HCV Cure - Long-term Support Needed for People Who Have Injected Drugs
- Details
- Category: Injection Drug Use
- Published on Wednesday, 10 June 2015 00:00
- Written by Keith Alcorn, Aidsmap
Reinfection rates after a hepatitis C cure among people who inject drugs, as well as past drug users, are relatively low, according to findings from studies from Norway and Canada presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress in Vienna in April. The findings suggest that current and former injection drug users who have been cured of hepatitis C require ongoing support to remain free of HCV, but also indicate that fears of a high rate of reinfection should not be used as a reason to withhold hepatitis C treatment from people who inject drugs.
EASL 2015: Milk Thistle May Improve Steatohepatitis, Capsaicin from Chili Peppers Helps Fibrosis
- Details
- Category: Steatosis/NAFLD/NASH
- Published on Wednesday, 13 May 2015 00:00
- Written by Liz Highleyman
People who used silymarin, derived from the milk thistle plant, experienced a resolution of non-alcoholic steatohepatitis (NASH) and a reduction in liver fibrosis in a randomized, placebo-controlled trial, researchers reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Another study found that dietary capsaicin, derived from chili peppers, was associated with improvement in mice with artificially induced fibrosis, the precursor to cirrhosis.
EASL 2015: Using Interferon with Hepatitis B Antivirals Raises Likelihood of HBsAg Loss
- Details
- Category: HBV Treatment
- Published on Tuesday, 09 June 2015 00:00
- Written by Liz Highleyman
Treating chronic hepatitis B with tenofovir plus pegylated interferon for 48 weeks resulted in a higher rate of hepatitis B surface antigen (HBsAg) clearance than either drug taken alone, though the response rate was still just 9%, according to a study presented at the recent European Association for the Study of the Liver (EASL) 50th International Liver Congress in Vienna. Other researchers reported that adding 48 weeks of interferon to nucleoside/nucleotide therapy increased the rate of HBsAg loss to about the same level, and switching to interferon may be effective for selected patients.
EASL 2015: Prenylation Inhibitor Lonafarnib Lowers Hepatitis Delta Viral Load During Therapy
- Details
- Category: Hepatitis Delta (HDV)
- Published on Tuesday, 12 May 2015 00:00
- Written by Liz Highleyman
Lonafarnib, a farnesyl transferase inhibitor that interferes with viral assembly, reduced hepatitis delta virus (HDV) levels by more than 3 log in a Phase 2 study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Combining lonafarnib with pegylated interferon for 8 weeks led to significantly greater HDV RNA declines than lonafarnib alone, but boosting with ritonavir achieved an even greater effect with an all-oral regimen. HDV viral load rose again after stopping therapy, however, and researchers are now evaluating longer treatment durations.
EASL 2015: Hepatitis C Treatment May Be Highly Cost-effective for Prisoners in England
- Details
- Category: HCV Treatment
- Published on Monday, 18 May 2015 00:00
- Written by Keith Alcorn, Aidsmap
Reducing the duration of direct-acting antiviral therapy for hepatitis C will make treatment for prisoners in England highly cost-effective, and could provide an important opportunity for providing access to hepatitis C treatment for people who inject drugs, Natasha Martin from the University of California San Diego reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.
EASL 2015: Shortening Triple Therapy to 6 Weeks Is Effective for Some Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Tuesday, 12 May 2015 00:00
- Written by Keith Alcorn
Shortening direct-acting antiviral therapy to 6 weeks for easier-to-treat patients without liver cirrhosis does not greatly reduce the efficacy of hepatitis C treatment for people with HCV genotype 1 infection, according to results of a study evaluating grazoprevir, elbasvir, and sofosbuvir (Sovaldi) in short treatment courses. Moreover, for people with HCV genotype 3 but no cirrhosis, an 8-week course of treatment was only marginally less effective than a 12-week course, even though genotype 3 infection is considered harder to treat.
DDW 2015/EASL 2015: Statins Associated with Lower Risk of Death and Liver Decompensation
- Details
- Category: HCV Disease Progression
- Published on Monday, 18 May 2015 00:00
- Written by Liz Highleyman
Hepatitis C patients with liver cirrhosis were significantly less likely to progress to decompensated disease and less likely to die if they used statins to control blood cholesterol, according to an analysis of U.S. veterans presented at the Digestive Disease Week meeting this week in Washington, DC, and at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Another recent study found that statins were associated with better response to hepatitis C treatment and lower risk of liver cancer.
EASL 2015: Sofosbuvir/ Ledipasvir Cures More Than 90% of People with Hepatitis C Genotypes 4 and 5
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 12 May 2015 00:00
- Written by Liz Highleyman
An interferon-free regimen of sofosbuvir and ledipasvir (Harvoni) produced sustained virological response rates of 93% for people with HCV genotype 4 and 95% for those with genotype 5, according to a French study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.
More Articles...
- EASL 2015: Heavy Drinkers Contribute Most to Liver Cirrhosis Burden; Heavy Alcohol Use Rising in U.S.
- EASL 2015: Nucleic Acid Polymer REP 2139-Ca Shows Promise Against Hepatitis B and Delta Viruses
- EASL 2015: Hepatitis C Treatment Effective for People with Advanced Liver Disease
- EASL 2015: Gilead Triple Combination Cures Easy-To-Treat Hepatitis C Patients in 6 Weeks
- EASL 2015: Sofosbuvir-based Therapy Effective for Hepatitis C Patients with Decompensated Cirrhosis
- EASL 2015: Civacir Immune Globulin May Help Prevent HCV Reinfection after Liver Transplant
- EASL 2015: People with Hepatitis C Have Higher Cancer Rates, Even When Excluding Liver Cancer
- Coverage of the 2015 EASL International Liver Congress
- EASL 2015: Paritaprevir and Ombitasvir Are Effective for Japanese Patients with HCV Genotype 1b
- EASL 2015: Heavy Alcohol Use Is Strongest Predictor of Liver Damage and Death in French Hepatitis C Patients
- EASL 2015: Another Study Confirms Detrimental Effects of Delaying Hepatitis C Treatment
- EASL 2015: Grazoprevir/ Elbasvir Combo Cures 99% of Hepatitis C Patients with Chronic Kidney Disease
- EASL 2015: Sofosbuvir-based Treatment Is Safe and Effective in Patients with Advanced Kidney Disease
- EASL 2015: Patients Who Fail Short Course of Sofosbuvir/Ledipasvir Can Be Cured with 24 Weeks
- EASL 2015: Grazoprevir/ Elbasvir Is Highly Effective for Previously Untreated Hepatitis C
- EASL 2015: Grazoprevir/ Elbasvir Effective for Treatment-Experienced and HIV/HCV Coinfected Patients
- EASL 2015: Advanced Liver Damage Is Common Among People with Undiagnosed Hepatitis C
- EASL 2015: Sofosbuvir + Interferon/Ribavirin Effective for Hard-to-Treat Genotype 3 HCV Patients
- EASL 2015: Sofosbuvir + Daclatasvir + Ribavirin Cures Advanced Cirrhosis and Liver Transplant Patients
- EASL 2015: Expanded Vaccination and Treatment Could Help Eliminate Hepatitis B Worldwide
- EASL 2015: New European Guidelines Prioritize Interferon-Free Hepatitis C Treatment
- EASL 2015: Sofosbuvir/ Ledipasvir + Ribavirin Cures Most Hepatitis C Patients with Advanced Liver Disease
- EASL 2015: Merck Hepatitis C Combination Achieves 90% Cure in Advanced Cirrhosis Patients
- EASL 2015: Merck HCV Combination Effective after Failure of First Generation Direct-Acting Antivirals
Web Design and Development by